company background image
65H logo

HTG Molecular Diagnostics DB:65H Stock Report

Last Price

€0.64

Market Cap

€5.8m

7D

0%

1Y

-96.4%

Updated

19 Mar, 2023

Data

Company Financials +

HTG Molecular Diagnostics, Inc.

DB:65H Stock Report

Market Cap: €5.8m

HTG Molecular Diagnostics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HTG Molecular Diagnostics
Historical stock prices
Current Share PriceUS$0.64
52 Week HighUS$24.72
52 Week LowUS$0.64
Beta1.05
1 Month Change0%
3 Month Change-91.91%
1 Year Change-96.44%
3 Year Change-98.82%
5 Year Change-99.90%
Change since IPO-99.94%

Recent News & Updates

Recent updates

Shareholder Returns

65HDE Healthcare ServicesDE Market
7D0%7.0%2.5%
1Y-96.4%-18.1%7.0%

Return vs Industry: 65H underperformed the German Healthcare Services industry which returned -10.2% over the past year.

Return vs Market: 65H underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 65H's price volatile compared to industry and market?
65H volatility
65H Average Weekly Movementn/a
Healthcare Services Industry Average Movement3.6%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 65H's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 65H's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199788John Lubniewskihttps://www.htgmolecular.com

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel.

HTG Molecular Diagnostics, Inc. Fundamentals Summary

How do HTG Molecular Diagnostics's earnings and revenue compare to its market cap?
65H fundamental statistics
Market cap€5.85m
Earnings (TTM)-€20.72m
Revenue (TTM)€6.38m

0.9x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
65H income statement (TTM)
RevenueUS$6.80m
Cost of RevenueUS$11.72m
Gross Profit-US$4.92m
Other ExpensesUS$17.18m
Earnings-US$22.09m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-9.99
Gross Margin-72.24%
Net Profit Margin-324.71%
Debt/Equity Ratio750.2%

How did 65H perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.